X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/biolinerx-announces-poster-presentation-on-apheresis-center-efficiency-and-cxcr4-antagonists-including-aphexda-motixafortide-in-patients-with-multiple-myeloma-at-the-asfa-2024-annual-meeting-302118663.html
https://www.prnewswire.com/news-releases/biolinerx-accesses-second-tranche-of-20-million-under-previously-announced-40-million-non-dilutive-debt-financing-agreement-302113022.html
https://www.prnewswire.com/news-releases/biolinerx-announces-6-million-registered-direct-offering-302104494.html
https://www.prnewswire.com/news-releases/biolinerx-reports-2023-financial-results-and-recent-corporate-and-portfolio-updates-302099418.html
https://www.prnewswire.com/news-releases/biolinerx-to-report-2023-annual-financial-results-on-march-26-2024-302094450.html
https://www.prnewswire.com/news-releases/im-cannabis-to-report-fourth-quarter-and-full-year-2023-financial-results-on-thursday-march-28-at-900am-et-302094367.html
https://www.prnewswire.com/news-releases/biolinerx-strengthens-intellectual-property-estate-with-notice-of-allowance-for-us-patent-covering-method-of-manufacturing-motixafortide-bl-8040-suitable-for-large-scale-production-302078254.html
https://www.prnewswire.com/news-releases/biolinerx-announces-first-patient-dosed-in-randomized-phase-2-combination-clinical-trial-evaluating-motixafortide-in-first-line-pancreatic-cancer-pdac-302073363.html
https://www.prnewswire.com/news-releases/biolinerx-announces-acceptance-of-two-poster-presentations-on-aphexda-motixafortide-for-cd34-hematopoietic-stem-cell-hsc-mobilization-in-patients-with-multiple-myeloma-at-the-2024-tandem-meetings-of-astct-and-cibmtr-302063517.html
https://www.prnewswire.com/news-releases/biolinerx-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-motixafortide-for-cd34-hematopoietic-stem-cell-mobilization-for-gene-therapies-in-sickle-cell-disease-302020452.html
Market Place
Share 
